Epithelial-mesenchymal transition, cancer stem cells and treatment resistance

Bhuvanesh Dave, Vivek Mittal, Nicholas M. Tan, Jenny C. Chang

Research output: Contribution to journalArticlepeer-review

192 Scopus citations


Breast cancer relapse, in a large number of patients, after initial response to standard of care therapy warrants development of novel therapies against recurrent and metastatic cancer. Cancer stem cells (CSCs), present in breast tumors while being intrinsically resistant to conventional therapy, have the ability to self renew and cause tumor recurrence. The residual tumors after therapy, with dramatic enrichment of the CSCs, have all the hallmarks of epithelial- mesenchymal transition (EMT). This review will focus on the link between EMT, CSCs and treatment resistance, since a better understanding of these interactions will allow us to effectively target the residual population after therapy.

Original languageEnglish
Article number202
JournalBreast Cancer Research
Issue number1
StatePublished - Jan 19 2012

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Epithelial-mesenchymal transition, cancer stem cells and treatment resistance'. Together they form a unique fingerprint.

Cite this